Research Solutions, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RSSS research report →
Range $3.5 – $4
Price Chart
About the company
Research Solutions, Inc. , through its subsidiaries, provides research cloud-based software-as-a-service software platform and related services to corporate, academic, government and individual researchers in the United States, Europe, and internationally. It provides Discover Tools that facilitates search discovery across virtually all scientific, technical, and medical (STM) articles available, including basic search solutions and advanced search tools comprising Resolute.
- CEO
- Roy W. Olivier
- IPO
- 2010
- Employees
- 136
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on RSSS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $73.58M
- P/E
- 15.61
- Fwd P/E
- 14.35
- PEG
- 0.02
- P/S
- 1.51
- P/B
- 3.65
- EV/EBITDA
- 9.76
- Div Yield
- 0.00%
- Gross Margin
- 50.10%
- Op Margin
- 7.97%
- Net Margin
- 9.28%
- ROE
- 27.45%
- ROIC
- 18.37%
Latest fiscal year · YoY change
- Revenue
- $49.06M+9.9%
- Gross Profit
- $24.20M+23.2%
- Op Income
- $2.50M
- Net Income
- $1.27M+133.4%
- EPS
- $0.04+131.7%
- OCF Growth
- +97.8%
- FCF Growth
- +101.3%
- 52W High
- $4.12
- 52W Low
- $2.00
- 50D MA
- $2.25
- 200D MA
- $2.53
- Beta
- 0.75
- RSI (14)
- 46
- Avg Volume
- 47.08K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Research Solutions posted improving profitability in fiscal Q3, but revenue fell on transaction churn even as platform ARR and AI-driven product momentum improved.· May 14, 2026
- Revenue was $12.1 million vs. $12.7 million a year ago, as platform subscription growth was offset by lower transaction revenue.
- Gross margin improved to 51.7% from 49.5% last year, helped by a mix shift toward higher-margin platform revenue.
- Net income rose to $860,000, or $0.03 per diluted share, and adjusted EBITDA increased to $1.6 million.
- ARR ended at $22.1 million, up 8.5% year over year; platform deployments and upsells supported growth.
- Management said churn remains the main top-line headwind, but sees early stabilization in transactions and stronger momentum from MCP-based AI products.
Total revenue for Q3 fiscal 2026 was $12.1 million, compared with $12.7 million in Q3 fiscal 2025. Platform subscription revenue increased approximately 7% to $5.2 million, while transaction revenue fell to $7.0 million from $7.8 million. Gross profit was $6.3 million, with gross margin of 51.7%, up 220 basis points year over year; platform gross margin was 86.4% and transaction gross margin was 26%. Net income was $860,000, or $0.03 per diluted share, versus $216,000, or $0.01 per diluted share, last year. Adjusted EBITDA was $1.6 million versus $1.4 million a year ago. Ending ARR was $22.1 million, up 8.5% year over year, and cash and cash equivalents were $12.1 million. For the quarter ahead, management said it expects Q4 improvement in year-over-year DocDel performance and aims to deliver adjusted EBITDA growth over the prior year, with stronger earnings power and cash generation exiting fiscal 2026.
Roy Olivier said the quarter was better on EBITDA and net income, but below expectations on top-line growth because churn remains an issue. He emphasized that new bookings were solid, including 61 new or upsell logos and sizable academic and corporate wins, and said the company is using AI internally to improve productivity and accelerate product releases. Olivier framed MCP-based products as central to the company’s headless strategy and future growth, saying AI will change how research is accessed rather than eliminate research.
Dave Kutil highlighted that the revenue decline came from weaker lower-margin transactions, while platform subscription revenue rose about 7% and represented about 43% of total revenue, up from about 38% a year ago. He noted gross margin improved to 51.7% from the prior year on mix shift, while platform gross margin remained 86.4% and transaction gross margin was 26%. He also pointed to disciplined spending, with operating expenses down to $5.2 million from $5.7 million, net income of $860,000, adjusted EBITDA of $1.6 million, and cash of $12.1 million with no revolver borrowings.
Analysts focused on B2B churn, B2C monetization, the AI road map, and whether new segments like financial institutions are gaining traction. Management said churn is mostly tied to low engagement, poor ROI, or lower DocDel usage, and outlined remedies including better onboarding, usage monitoring, proactive re-engagement, and feature education. On B2C, management said digital ad spend is down materially, conversion improved, retention improved after MCP launches, and CAC fell about 24%; on AI, they described a usage-based pricing approach and said MCP usage is running at a multiple of core-platform usage. On new markets, Roy said the company has only a few customers in financial services and is staying focused on corporate and academic sales for now.
The bull case from this call is that platform revenue, ARR, margins, and profitability are all improving even while total revenue is temporarily pressured by transaction churn. Management also sees early stabilization in transaction trends, better B2C conversion and retention, and a meaningful pipeline around MCP-based products, with more than $1 million in opportunities. The AI strategy appears to be gaining real customer interest, supported by internal productivity gains and new product launches.
The main bear case is that top-line growth is still being held back by churn, including one larger account and multiple smaller accounts, and management said fixing it will take more than a quarter. Transaction revenue is still down, active transaction customers declined to 1,346 from 1,380, and B2C remains seasonally weak as summer approaches. Management also said M&A is difficult at current multiples and that new vertical expansion is not yet a priority, which could limit near-term growth avenues.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.3%
- Shares Outstanding
- 33.45M
- Float Shares
- 25.17M
of shares held by institutions
40 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cove Street Capital, LLC | 1.34M | ▼ 1.08K |
| Vanguard Group Inc | 1.26M | ▲ 9.96K |
| Perritt Capital Management Inc | 356.82K | 0 |
| Dhk Financial Advisors, Inc. | 118.76K | 0 |
| Cubist Systematic Strategies, LLC | 11.36K | ▲ 11.36K |
Held by 29 ETFs
Biggest fund positions in RSSS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | Cohen Sefton | sell | 284,000 |
| Mar 18, 26 | Cohen Sefton | other | 80,000 |
| Dec 10, 25 | Kutil David | other | 30,000 |
| Dec 19, 25 | Kutil David | other | 758 |
| Dec 10, 25 | Kutil David | other | 0 |
| Nov 12, 25 | Gayron Kenneth L | other | 50,000 |
| Nov 12, 25 | MCPEAK MERRILL A | other | 75,000 |
| Nov 12, 25 | MCPEAK MERRILL A | other | 50,000 |
| Nov 12, 25 | MCPEAK MERRILL A | other | 75,000 |
| Nov 17, 25 | Regazzi John J | other | 150,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RSSS coverage
Recent articles, reports, and earnings notes.
No research on RSSS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RSSS report →Research Solutions to Participate at Upcoming Investor Conferences
prnewswire.com · Aug 18
The Russell 2000 Just Did Something for the First Time Since 1991. Here's Why Investors Should Pay Attention.
fool.com · Jul 6
Element Biosciences Announces Upsized Series E to Accelerate Global Growth Across Ecosystem of Genomic, Multiomic, and Clinical Research Solutions
businesswire.com · Jun 9
Research Solutions to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10th in New York, NY
prnewswire.com · Jun 4
Research Solutions Q3 Earnings Call Highlights
marketbeat.com · May 14
Research Solutions, Inc. (RSSS) Q3 2026 Earnings Call Transcript
seekingalpha.com · May 14
Research Solutions Inc. (RSSS) Matches Q3 Earnings Estimates
zacks.com · May 14
Research Solutions Reports Third Quarter Fiscal Year 2026 Results
prnewswire.com · May 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.